Status:
TERMINATED
Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With CF-LVAD
Lead Sponsor:
University of Chicago
Conditions:
Heart Failure
Gastrointestinal Bleeding
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This study evaluates the efficacy of high-dose fish oil in decreasing rates of gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices. Half of the patients without ...
Detailed Description
A potential mechanism of bleeding in patients with continuous-flow left ventricular assist devices (CF-LVAD) is dysfunctional angiogenesis. Angiogenesis is a complicated process controlled by several ...
Eligibility Criteria
Inclusion
- Subject has signed consent
- Age \> 18 years
- Subjects with a CF-LVAD or are scheduled to receive a CF-LVAD implant
Exclusion
- Psychiatric disorder or disease, irreversible cognitive dysfunction or psychosocial issues that might impair compliance with the study.
- Patients already taking fish oil.
Key Trial Info
Start Date :
January 23 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 15 2020
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT03784963
Start Date
January 23 2019
End Date
July 15 2020
Last Update
July 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Chicago Medicine
Chicago, Illinois, United States, 60637